Literature DB >> 9094681

A novel virus binding assay using confocal microscopy: demonstration that the intracellular and extracellular vaccinia virions bind to different cellular receptors.

A Vanderplasschen1, G L Smith.   

Abstract

Vaccinia virus (VV) produces two antigenically and structurally distinct infectious virions, intracellular mature virus (IMV) and extracellular enveloped virus (EEV), which bind to unidentified and possibly different cellular receptors. Studies of VV binding have been hampered by having two infectious virions and by the rupture of the EEV outer membrane in the majority of EEV virions during purification. To overcome these problems, we have developed a novel approach to study VV binding that is based on confocal microscopy and does not require EEV purification. In this assay, individual virus particles adsorbed to the cell are simultaneously distinguished and quantified by double immunofluorescence labelling with antibody markers for EEV and IMV. By this method, we show unequivocally that IMV and EEV bind to different cellular receptors. Three independent observations allow this conclusion. First, the efficiencies with which IMV and EEV bind to different cell lines are unrelated; second, cell surface digestion with some enzymes affects IMV and EEV binding differently; and third, the binding of a monoclonal antibody to cells prevents IMV binding but not EEV binding. This technique may be widely applicable for studying the binding of different viruses.

Mesh:

Substances:

Year:  1997        PMID: 9094681      PMCID: PMC191556     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

Review 1.  Differences between extracellular and intracellular forms of poxvirus and their implications.

Authors:  E A Boulter; G Appleyard
Journal:  Prog Med Virol       Date:  1973

2.  An antigenic difference between intracellular and extracellular rabbitpox virus.

Authors:  G Appleyard; A J Hapel; E A Boulter
Journal:  J Gen Virol       Date:  1971-10       Impact factor: 3.891

3.  Protection against poxviruses.

Authors:  E A Boulter
Journal:  Proc R Soc Med       Date:  1969-03-03

4.  Neutralizing activities of antisera to poxvirus soluble antigens.

Authors:  G Appleyard; C Andrews
Journal:  J Gen Virol       Date:  1974-05       Impact factor: 3.891

5.  Biogenesis of poxviruses: role of A-type inclusions and host cell membranes in virus dissemination.

Authors:  Y Ichihashi; S Matsumoto; S Dales
Journal:  Virology       Date:  1971-12       Impact factor: 3.616

6.  Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies.

Authors:  C P Czerny; H Mahnel
Journal:  J Gen Virol       Date:  1990-10       Impact factor: 3.891

7.  A novel immunogold cryoelectron microscopic approach to investigate the structure of the intracellular and extracellular forms of vaccinia virus.

Authors:  N Roos; M Cyrklaff; S Cudmore; R Blasco; J Krijnse-Locker; G Griffiths
Journal:  EMBO J       Date:  1996-05-15       Impact factor: 11.598

8.  Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia.

Authors:  L G Payne
Journal:  J Gen Virol       Date:  1980-09       Impact factor: 3.891

9.  Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus.

Authors:  L G Payne
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

10.  Supercoils in human DNA.

Authors:  P R Cook; I A Brazell
Journal:  J Cell Sci       Date:  1975-11       Impact factor: 5.285

View more
  50 in total

1.  Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus.

Authors:  M I Vázquez; M Esteban
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Using confocal microscopy to study virus binding and entry into cells.

Authors:  A Vanderplasschen; G L Smith
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

3.  Vaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.

Authors:  W H Zhang; D Wilcock; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Entry of the two infectious forms of vaccinia virus at the plasma membane is signaling-dependent for the IMV but not the EEV.

Authors:  J K Locker; A Kuehn; S Schleich; G Rutter; H Hohenberg; R Wepf; G Griffiths
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

5.  Relationship between vaccinia virus intracellular cores, early mRNAs, and DNA replication sites.

Authors:  Massimo Mallardo; Edward Leithe; Sibylle Schleich; Norbert Roos; Laura Doglio; Jacomine Krijnse Locker
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex.

Authors:  Suany Ojeda; Arban Domi; Bernard Moss
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Poxvirus multiprotein entry-fusion complex.

Authors:  Tatiana G Senkevich; Suany Ojeda; Alan Townsley; Gretchen E Nelson; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-08       Impact factor: 11.205

8.  The product of the vaccinia virus L5R gene is a fourth membrane protein encoded by all poxviruses that is required for cell entry and cell-cell fusion.

Authors:  Alan C Townsley; Tatiana G Senkevich; Bernard Moss
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Development and comparison of a quantitative TaqMan-MGB real-time PCR assay to three other methods of quantifying vaccinia virions.

Authors:  Jonathon L Baker; Brian M Ward
Journal:  J Virol Methods       Date:  2013-11-08       Impact factor: 2.014

10.  DNA packaging mutant: repression of the vaccinia virus A32 gene results in noninfectious, DNA-deficient, spherical, enveloped particles.

Authors:  M C Cassetti; M Merchlinsky; E J Wolffe; A S Weisberg; B Moss
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.